Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 100 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $64,223 | -19.7% | 11,784 | 0.0% | 0.00% | – |
| Q2 2023 | $80,013 | +18.0% | 11,784 | -12.9% | 0.00% | – |
| Q1 2023 | $67,785 | -3.2% | 13,530 | -5.7% | 0.00% | – |
| Q4 2022 | $70,023 | -71.1% | 14,349 | -14.6% | 0.00% | – |
| Q3 2022 | $242,000 | -86.1% | 16,803 | -85.4% | 0.00% | -100.0% |
| Q2 2022 | $1,745,000 | +869.4% | 115,302 | +661.4% | 0.00% | – |
| Q1 2022 | $180,000 | -26.2% | 15,144 | +0.7% | 0.00% | – |
| Q4 2021 | $244,000 | -48.0% | 15,033 | -8.5% | 0.00% | – |
| Q3 2021 | $469,000 | +0.2% | 16,429 | +18.5% | 0.00% | – |
| Q2 2021 | $468,000 | +82.1% | 13,866 | +63.1% | 0.00% | – |
| Q1 2021 | $257,000 | -18.2% | 8,503 | +34.2% | 0.00% | – |
| Q4 2020 | $314,000 | -91.5% | 6,334 | -92.6% | 0.00% | -100.0% |
| Q2 2020 | $3,674,000 | – | 85,061 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 216,916 | $6,191,000 | 3.86% |
| Sofinnova Investments, Inc. | 2,194,278 | $62,625,000 | 3.71% |
| MPM BioImpact LLC | 452,970 | $12,928,000 | 2.00% |
| Soleus Capital Management, L.P. | 265,700 | $7,583,000 | 1.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 452,110 | $12,903,000 | 1.17% |
| ORACLE INVESTMENT MANAGEMENT INC | 315,642 | $9,008,000 | 1.12% |
| First Light Asset Management, LLC | 577,663 | $16,487,000 | 1.09% |
| Lombard Odier Asset Management (Switzerland) SA | 352,839 | $10,070,000 | 0.62% |
| Cormorant Asset Management, LP | 500,000 | $14,270,000 | 0.58% |
| Artal Group S.A. | 400,000 | $11,416,000 | 0.26% |